title: [The causes of intracranial hemorrhagic complications induced by antivitamins K].
abstract: Cerebral haemorrhage is the main life-threatening complication of oral anticoagulant therapy. In order to identify a means of prevention, the authors undertook a retrospective study of 68 consecutive cases of anticoagulant-related intracerebral haemorrhage. The mortality was 38.5%. The respective frequency of intracerebral haemorrhage, subarachnoid haemorrhage, acute and chronic subdural haematomas was 63.2, 16.2, 10.3 and 10.3%, respectively. On admission, nearly half the patients (53%) had prothrombin ratios inferior to 25%. A predisposing factor was found in 58% of cases: hypertension (30.6%), head injury (14.5%), alcoholism or drug interaction (11.2%), and one case of intracerebral aneurysm. A history of a transient ischaemic attack or of a cerebrovascular accident was found in 10.2% of cases and 11.7% had a previous anticoagulant related extracranial haemorrhage. The initial indications for oral anticoagulation were ischaemic heart disease (32%), atrial fibrillation (20.5%), secondary prevention of venous thromboembolic disease (17.6%) and primary prevention of venous thrombosis (11.7%). The duration of treatment for isolated ischaemic heart disease was over 6 months in all cases: the average duration of treatment was 12.4 months in phlebitis and pulmonary embolism. A critical review of the indications of treatment in the light of recent recommendations showed that if inappropriate indications were rare, the sometimes unnecessary prolongation of treatment was more common. Nearly half of these cases were receiving anticoagulants when the potential benefits were questionable at the time of the haemorrhagic complication. Clinical and biological follow-up is necessary for patients on anticoagulants; minor bleeding complications may be the prelude to major haemorrhage. Biological follow-up is based on control of the international normalised ratio.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Service de CTCV et angiologie, CHRU Dupuytren, Limoges.
authors.forename: P
authors.initials: P
authors.lastname: Lacroix
authors.forename: O
authors.initials: O
authors.lastname: Portefaix
authors.forename: M
authors.initials: M
authors.lastname: Boucher
authors.forename: H
authors.initials: H
authors.lastname: Ramiandrisoa
authors.forename: M
authors.initials: M
authors.lastname: Dumas
authors.forename: R
authors.initials: R
authors.lastname: Ravon
authors.forename: C
authors.initials: C
authors.lastname: Christides
authors.forename: M
authors.initials: M
authors.lastname: Laskar
mesh_terms: D015110:4-Hydroxycoumarins; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000209:etiology / Q000401:mortality; D005260:Female; D006801:Humans; D007192:Indenes; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D015110:4-Hydroxycoumarins; D000925:Anticoagulants; D007192:Indenes; C011664:antivitamins K; D014812:Vitamin K
vernacular_title: Conditions de survenue des accidents hémorragiques intracrâniens des antivitamines K.